ONTARIO, Calif., Aug. 9, 2004 (PRIMEZONE) -- LifePoint, Inc.(r) (AMEX:LFP), a leader in non-invasive drug diagnostic technologies and solutions, today announced that the Hendricks County Circuit Court in Danville, Indiana has signed a three-year agreement for use of the IMPACT(r) Test System. The IMPACT Test System will be used by probation officers to test juveniles and other individuals under the supervision of the County Probation Department.
"The IMPACT Test System is being introduced into both our preliminary and continuing drug test programs," stated Stephen Schmalz, Director of Hendricks County Circuit Court Probation Department. "Besides the obvious advantage of being able to test almost anywhere without the need for a bathroom or an observed urine sample (major benefits when testing juveniles), the IMPACT Test System helps make concealing illegal drug use a lot harder to do. It has proven to be a great tool and we expect it to improve our ability to detect illicit drug use and may prove to be an additional deterrent."
Linda Masterson, President & CEO of LifePoint stated, "We are very pleased to be working with the Hendricks County Probation Department and providing them with a solution to greatly improve the overall effectiveness of their drug testing program. Saliva testing for drug abuse revolutionizes a process that until now has been mired in inefficiency for many years. Urine tests are difficult to administer, require gender specific collections, and are subject to substitution and adulteration of the sample by the donor. Testing saliva using the Impact system removes these administrative hurdles from day-to-day testing regimens and enables law enforcement officers to more efficiently manage their time and resources."
About LifePoint, Inc.
LifePoint, Inc., a leader in non-invasive drug diagnostic technologies and solutions, has developed, manufactures and markets the IMPACT Test System - a rapid diagnostic testing, screening and drug monitoring device for use in law enforcement and the workplace, and in the future, ambulances, pharmacies, and home healthcare markets. LifePoint's patented and proprietary technologies for the use of saliva as a non-invasive, blood-comparable test specimen, used in conjunction with the flow immunosensor technology licensed from the United States Navy, have allowed LifePoint to develop a broadly applicable, rapid, on-site diagnostic test system. The first product simultaneously detects drugs of abuse and alcohol. The initial three target markets - law enforcement, industrial workplace and medical emergency room - are estimated at over $1.6 billion in total sales opportunity.
This press release contains forward-looking statements regarding future events and the future performance of LifePoint, Inc. that involve risks and uncertainties that could cause actual results to differ materially. Although the Company believes that the expectations reflected in any forward-looking statements made herein are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. The Company undertakes no obligation to update any forward-looking statements made to conform to actual results or to changes to expectations. These risks include, but are not limited to the potential need for additional financing, FDA 510(k) clearance in medical markets, dependence on third parties for certain marketing efforts, and market acceptance. These risks and others are described in further detail in the Company's reports filed with the Securities and Exchange Commission.
LifePoint(r) and IMPACT(r) are trademarks of LifePoint, Inc.